Corporate News

INMUNOTEK Symposium at the 42nd SEI Congress

March 2021

Within the 42nd congress of the SEI (Spanish Society of Immunology) INMUNOTEK has organized a satellite symposium on trained immunity-based vaccines (TIbV) that act through mucosa and their potential role against respiratory infections of viral origin.
More info

Industrial doctorates in the Community of Madrid

Comunidad MadridFebruary 2021

The Department of Science, Universities and Innovation of the Community of Madrid, has held a meeting with INMUNOTEK to evaluate the industrial doctorate program. This program is an initiative of the executive of the Community of Madrid to promote public-private collaboration through the completion of doctoral theses in an academic and business environment.
More info

INMUNOTEK listed in the 2020 edition of CEPYME500

cepyme500 2020December 2020

INMUNOTEK listed in CEPYME500, 2020 edition. This is an initiative of CEPYME (State Confederation of Small and Medium Enterprises) to identify, recognize and support the 500 leading companies in business growth in Spain. INMUNOTEK was already listed in 2017.
More info

European Patent Granted

EPODecember 2020

The European Patent Office has granted to INMUNOTEK the patent EP2982381B1. This refers to hypoallergenic neoglycoconjugates performed with non-oxidized mannan derived from S. cerevisiae to be used for the development of novel allergy vaccines targeting dendritic cells.
More info

CIEGE Seal for INMUNOTEK at Business Excellence

Sello IeENovember 2020

INMUNOTEK obtains the CIEGE Seal for excellence in business management for the second consecutive year. This Seal certifies excellent management over 57 indicators from 10 categories: solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization.
More info